AGP Picks
View all

Texas Technology Digest
Provided by AGP

Texas Technology Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Texas Technology Digest.

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

July 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

Press releases published on August 12, 2026

Kamada Announces Planned Transition of Chief Financial Officer
Aug. 12, 2026

Kamada Announces Planned Transition of Chief Financial Officer

Indeterminate GlobeNewswire
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights
Aug. 12, 2026

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

Indeterminate GlobeNewswire
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer
Aug. 12, 2026

LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer

Indeterminate GlobeNewswire
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
Aug. 12, 2026

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

Indeterminate GlobeNewswire
Zapata Quantum Partners with QuEra to Advance the Commercial Viability of Quantum Applications
Aug. 12, 2026

Zapata Quantum Partners with QuEra to Advance the Commercial Viability of Quantum Applications

Indeterminate GlobeNewswire
Persephone Biosciences Publishes Largest U.S. Clinical Study of an Infant Synbiotic in Pediatric Research, Expanding Clinical Evidence for Its Infant Synbiotics
Aug. 12, 2026

Persephone Biosciences Publishes Largest U.S. Clinical Study of an Infant Synbiotic in Pediatric Research, Expanding Clinical Evidence for Its Infant Synbiotics

Indeterminate GlobeNewswire
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
Aug. 12, 2026

Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates

Indeterminate GlobeNewswire
Aurora Mobile's Modellix Adds PixVerse V6: Finished-Grade Video in One Request
Aug. 12, 2026

Aurora Mobile's Modellix Adds PixVerse V6: Finished-Grade Video in One Request

Indeterminate GlobeNewswire
RedCloud Signs India MOUs to Deploy Its RAID and CORE Engines Targeting 11 Apparel Brands, 25,000+ SKUs and 1,250+ Buyer Points
Aug. 12, 2026

RedCloud Signs India MOUs to Deploy Its RAID and CORE Engines Targeting 11 Apparel Brands, 25,000+ SKUs and 1,250+ Buyer Points

Indeterminate GlobeNewswire
Qintess Commits to a Minimum $6.5 Million Spend on Fusemachines Agentic AI Products and Services Over Three Years
Aug. 12, 2026

Qintess Commits to a Minimum $6.5 Million Spend on Fusemachines Agentic AI Products and Services Over Three Years

Indeterminate GlobeNewswire
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug. 12, 2026

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Indeterminate GlobeNewswire
Einride and DAF Partner to Accelerate Scale-up of Autonomous Electric Freight
Aug. 12, 2026

Einride and DAF Partner to Accelerate Scale-up of Autonomous Electric Freight

Indeterminate GlobeNewswire
EarthDaily Awarded Canadian Government Contract to Develop AI-Enabled Border Monitoring Demonstration Platform
Aug. 12, 2026

EarthDaily Awarded Canadian Government Contract to Develop AI-Enabled Border Monitoring Demonstration Platform

Indeterminate GlobeNewswire
Liquidia Corporation Reports Second Quarter 2026 Financial Results
Aug. 12, 2026

Liquidia Corporation Reports Second Quarter 2026 Financial Results

Indeterminate GlobeNewswire
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Aug. 12, 2026

Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones

Indeterminate GlobeNewswire
Global-e Achieves Significant GMV, Revenue and Profit Expansion in the Second Quarter of 2026, Raises Outlook for the Year
Aug. 12, 2026

Global-e Achieves Significant GMV, Revenue and Profit Expansion in the Second Quarter of 2026, Raises Outlook for the Year

Indeterminate GlobeNewswire
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
Aug. 12, 2026

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

Indeterminate GlobeNewswire
NiaKai Announces Market Arrival with Five Signed Early-Adopter Agreements
Aug. 12, 2026

NiaKai Announces Market Arrival with Five Signed Early-Adopter Agreements

Indeterminate GlobeNewswire
MyyShop Launches “Paid for Every View” TikTok CPM Model to Give Creators Faster, More Transparent Monetization Opportunities
Aug. 12, 2026

MyyShop Launches “Paid for Every View” TikTok CPM Model to Give Creators Faster, More Transparent Monetization Opportunities

Indeterminate GlobeNewswire
Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases
Aug. 12, 2026

Expanded Access Case Report of SNIPR001, an Engineered CRISPR Medicine, in Rare Intracellular E. coli Disease Published in Clinical Infectious Diseases

Indeterminate GlobeNewswire
Show More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Texas Technology Digest

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.